Trade Valneva SE - VLA CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.03
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.01802 %(-€0.90)Trade size with leverage ~ €5,000.00Money from leverage ~ $€4,000.00Go to platform: -0.01802%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.00420 %(-€0.21)Trade size with leverage ~ €5,000.00Money from leverage ~ $€4,000.00Go to platform: -0.00420%
• Overnight funding adjustment time: 22:00 (UTC)
• Currency: EUR
• Min traded quantity: 10
• Margin: 20.00%
• Stock exchange: France
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.01802 %
  (-€0.90)

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00420 %
  (-€0.21)

Key Stats

• Prev. Close: 2.58
• Open: 2.55
• 1-Year Change: -31.45%
• Day's Range: 2.55 - 2.66

Trade Valneva SE - VLA

About Valneva SE

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Financial summary

BRIEF: For the six months ended 30 June 2021, Valneva SE revenues decreased 1% to EUR47.5M. Net loss applicable to common stockholders increased from EUR25.6M to EUR86.4M. Revenues reflect Commercialized Vaccines segment decrease of 22% to EUR31.8M, Canada segment decrease of 75% to EUR2M, United Kingdom segment decrease of 75% to EUR1.1M, Europe excluding France segment decrease of 42% to EUR4.2M.

Equity composition

07/2010, Rights Issue, 2 new shares for every 5 shares held @ EUR 5.06 (Factor: 1.12817). 6/2013, Rights Issue, 5 new shares for every 13 shares held @ EUR2.65 (Factor: 1.11881). 1/2015, Rights Issue, 11 new shares for every 34 shares held @ EUR2.47 (Factor: 1.10896).